Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy.

Y-Y ShaoB-B ChenD-L OuZ-Z LinC-H HsuM-J WangA-L ChengChiun Hsu

Published in: Alimentary pharmacology & therapeutics (2017)

Lenalidomide exhibited moderate activity as second-line therapy for advanced HCC. Its immunomodulatory effects should be further explored (www.clinicaltrials.gov NCT01545804).